AdAlta (ASX:1AD) is abandoning internal research activities for the AD-214 antifibrotic drug to focus on its "East to West" strategy for cellular immunotherapy, according to a Thursday filing with the Australian bourse.
Following a strategic review, the company decided to cease internal discovery research and development activities for AD-214. It will still pursue the drug but only through third parties, per the filing.
Instead, AdAlta will focus on accelerating its cellular immunotherapy strategy, with two new non-binding term sheets to in-license clinical-stage CAR-T products, the filing said.
Under the agreements, AdAlta will in-license highly differentiated cell therapies for solid cancers from Asian originators and conduct Phase I clinical trials, giving it a pathway to access Western markets, the filing said.
The clinical-stage biotechnology firm's shares fell 6% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.